It generally has a half-life (how long it takes your body to clear 50% of the substance from your system) of around five hours, though this varies substantially
Department of Health and Human Services General Counsel Mike Stuart said he referred Hims & Hers to the Department of Justice for an investigation over potential violations
2025 Essential drug list 3-tier, Anthem Blue Cross Blue Shield New York (2025) 2024 Individual & Family Metal Plans Base, Simply Blue Plus and College Blue Plans Formulary Guide (2981), Excellus Blue Cross Blue Shield (2024) Check our drug list/formulary, Excellus Blue Cross Blue Shield (2025) 2025 Drug lists for Medicare members, Blue Cross Blue Shield Blue Care Network of Michigan (2025) Formulary (list of drugs), Blue Cross Community Health Plans (2025) Preferred drug list, Blue Cross Complete of Michigan (2025) FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, Food and Drug Administration (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice

Cost Comparison Table Insurance Coverage Saxenda: FDA-approved for weight loss Some plans cover with prior authorization May have quantity limits or step therapy requirements Ozempic: FDA-approved for diabetes, not weight loss Often covered for diabetic patients Rarely covered for weight loss alone Wegovy: FDA-approved for weight loss Coverage varies widely Many plans exclude weight loss medications Cost Efficiency When comparing cost per outcome: Saxenda: At $200/month for 12 months ($2,400) producing 15-18 pounds loss = ~$133-160 per pound lost Semaglutide: At $199/month for 12 months ($2,388) producing 30-35 pounds loss = ~$68-80 per pound lost Semaglutide provides substantially better value when considering weight loss achieved per dollar spent
This once-weekly GLP-1 receptor agonist is licensed in the UK for weight management in adults with obesity or overweight with weight-related comorbidities